《专利态势报告：COVID-19相关疫苗和疗法》-85页_2mb

报告摘要

COVID-19 Vaccines and Therapeutics Patent Landscape Report Summary

This report by the World Intellectual Property Organization (WIPO) analyzes the patent landscape for COVID-19 vaccines and therapeutics from January 2020 through September 2022.

Key Findings

Over 7,758 COVID-19-related patents were filed globally, with ~4,787 for therapeutics and ~1,298 for vaccines.
Patenting activity peaked in April 2020 and reflected unprecedented speed in vaccine development (emergency use approvals achieved within 14 months).
Companies filed ~52% of vaccine patents, while universities/research organizations accounted for ~42%.
China was the largest filer (~3,000 applications), followed by the US, Republic of Korea, Germany and India.

Patent Distribution

Vaccines: mRNA (47% of patents, but used in <1% of doses), protein subunit (47% of vaccines patented), viral vector (21%).
Therapeutics: Small molecules (50%) and biologics (43%) dominate; traditional medicine accounts for ~10%.
Patent offices: WIPO/PCT (40% of vaccines, 26% of therapeutics), China National IP Administration (CNIPA) (28% vaccines, 23% therapeutics), USPTO (14% vaccines).

Notable Trends

mRNA vaccines discussed heavily in global media but represent only ~11% of patent filings.
Accelerated patent examination and fee relief programs supported IP systems during the pandemic.
Booster vaccines account for only ~5% of vaccine patents despite high public discussion and usage.

Collaborations

Extensive partnerships between academic institutions, research organizations, and pharmaceutical companies accelerated vaccine development.
Notable MPP and GHIAA initiatives facilitated equitable licensing and technology transfer.

Challenges

Significant equity issues in vaccine distribution, with high-income countries accounting for ~60% of vaccinations globally.
Complex IP landscape and patent thickets around mRNA technology (e.g., Moderna vs. Pfizer/BioNTech disputes).

Future Directions

Ongoing development of bivalent boosters and pan-coronavirus vaccines addresses evolving variants.
Growing application of AI and gene-editing technologies like CRISPR.

This report underscores the unprecedented pace of innovation during the pandemic while also highlighting key challenges in equitable access and continued technological evolution.

展开完整摘要